A short-term mouse model that reproduces the immunopathological features of rhinovirus-induced exacerbation of COPD

Autor: Jay C. Horvat, Julia Aniscenko, Nathan W. Bartlett, Philip M. Hansbro, Rebecca M. Pearson, Aran Singanayagam, Nicholas Glanville, Sebastian L. Johnston, James W. Pinkerton, Ross P. Walton
Přispěvatelé: Wellcome Trust
Rok vydání: 2015
Předmět:
Lipopolysaccharides
Chemokine
Time Factors
Exacerbation
Rhinovirus
MPO
myeloperoxidase

Research & Experimental Medicine
Inflammatory responses
TNF
tumour necrosis factor

IP-10
interferon γ-induced protein 10

Experimental emphysema
FRC
functional residual capacity

Pulmonary Disease
Chronic Obstructive

exacerbation
Medicine
Obstructive pulmonary-disease
COPD
biology
Haemophilus-influenzae
General Medicine
11 Medical And Health Sciences
S10
AHR
airway hyper-responsiveness

CXCL10
C-X-C motif chemokine 10

Medicine
Research & Experimental

H&E
haematoxylin and eosin

LPS
lipopolysaccharide

Tumor necrosis factor alpha
Female
BAL
bronchoalveolar lavage

medicine.symptom
Chemokines
Life Sciences & Biomedicine
CCL5
chemokine (C-C motif) ligand 5

Inflammation
MIP-2
macrophage inflammatory protein 2

S8
RANTES
regulated on activation
normal T-cell expressed and secreted

CCL5
Proinflammatory cytokine
chronic obstructive pulmonary disease
PAS
periodic acid–Schiff

CXCL10
Animals
IFN
interferon

mouse models
Original Paper
Science & Technology
Picornaviridae Infections
business.industry
TLC
total lung capacity

medicine.disease
RV
rhinovirus

Asthma
IL
interleukin

Airway epithlial-cells
Mice
Inbred C57BL

Disease Models
Animal

COPD
chronic obstructive pulmonary disease

Cardiovascular System & Hematology
inflammation
Immunology
biology.protein
PFA
paraformaldehyde

business
Zdroj: Clinical Science (London, England : 1979)
Popis: Viral exacerbations of chronic obstructive pulmonary disease (COPD), commonly caused by rhinovirus (RV) infections, are poorly controlled by current therapies. This is due to a lack of understanding of the underlying immunopathological mechanisms. Human studies have identified a number of key immune responses that are associated with RV-induced exacerbations including neutrophilic inflammation, expression of inflammatory cytokines and deficiencies in innate anti-viral interferon. Animal models of COPD exacerbation are required to determine the contribution of these responses to disease pathogenesis. We aimed to develop a short-term mouse model that reproduced the hallmark features of RV-induced exacerbation of COPD. Evaluation of complex protocols involving multiple dose elastase and lipopolysaccharide (LPS) administration combined with RV1B infection showed suppression rather than enhancement of inflammatory parameters compared with control mice infected with RV1B alone. Therefore, these approaches did not accurately model the enhanced inflammation associated with RV infection in patients with COPD compared with healthy subjects. In contrast, a single elastase treatment followed by RV infection led to heightened airway neutrophilic and lymphocytic inflammation, increased expression of tumour necrosis factor (TNF)-α, C-X-C motif chemokine 10 (CXCL10)/IP-10 (interferon γ-induced protein 10) and CCL5 [chemokine (C-C motif) ligand 5]/RANTES (regulated on activation, normal T-cell expressed and secreted), mucus hypersecretion and preliminary evidence for increased airway hyper-responsiveness compared with mice treated with elastase or RV infection alone. In summary, we have developed a new mouse model of RV-induced COPD exacerbation that mimics many of the inflammatory features of human disease. This model, in conjunction with human models of disease, will provide an essential tool for studying disease mechanisms and allow testing of novel therapies with potential to be translated into clinical practice.
The present study describes a new short-term mouse model of rhinovirus (RV)-induced exacerbation of COPD (chronic obstructive pulmonary disease) which will facilitate insight into disease mechanisms and could provide a more efficient tool to test novel therapies with potential to be translated into clinical practice.
Databáze: OpenAIRE